Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.55 |
| ▸ | CXCR3 | P49682 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169552 | 0.88 | TAS2R14 (0.64) | TAS2R14CXCR3MEN1KMT2APSEN1 | |
| SCHEMBL1169800 | 0.87 | CXCR3 (0.67) | TAS2R14CXCR3MEN1KMT2ANR1H2 | |
| SCHEMBL1169691 | 0.87 | CXCR3 (0.58) | TAS2R14CXCR3MEN1KMT2APSEN1 | |
| SCHEMBL1169299 | 0.85 | CXCR3 (0.56) | TAS2R14CXCR3MEN1KMT2ANR1H2 | |
| SCHEMBL1169773 | 0.83 | CXCR3 (0.60) | TAS2R14CXCR3MEN1KMT2APSEN1 | |
| SCHEMBL12863751 | 0.83 | CXCR3 (0.54) | TAS2R14CXCR3MEN1KMT2ANR1H2 | |
| SCHEMBL1169722 | 0.81 | TAS2R14 (0.53) | TAS2R14CXCR3MEN1KMT2ANR1H2 | |
| SCHEMBL1169226 | 0.80 | TAS2R14 (0.59) | TAS2R14CXCR3MEN1KMT2ANR1H2 | |
| SCHEMBL1169495 | 0.79 | NR1H2 (0.63) | TAS2R14CXCR3MEN1KMT2ANR1H2 | |
| SCHEMBL1169107 | 0.79 | CXCR3 (0.60) | TAS2R14CXCR3PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2009124962-A2 | SULFONAMIDES | MERCK SERONO S.A. (CH) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028509-A1 | Sulfonamides | CXCR3, CXCR2, CXCR1 | TAS2R14 517/4885CXCR3 1/4885MEN1 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.